

SFRP1 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP9037a**Specification****SFRP1 Antibody (N-term) Blocking Peptide -
Product Information**Primary Accession [Q8N474](#)**SFRP1 Antibody (N-term) Blocking Peptide -
Additional Information****Gene ID** 6422**Other Names**Secreted frizzled-related protein 1, FRP-1,
sFRP-1, Secreted apoptosis-related protein
2, SARP-2, SFRP1, FRP, FRP1, SARP2**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP9037a](/products/AP9037a) was selected from the N-term region of human SFRP1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SFRP1 Antibody (N-term) Blocking Peptide -
Protein Information****Name** SFRP1**SFRP1 Antibody (N-term) Blocking Peptide
- Background**

SFRP1 encodes a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins. Members of this family act as soluble modulators of Wnt signaling; epigenetic silencing of SFRP genes leads to deregulated activation of the Wnt-pathway which is associated with cancer.

**SFRP1 Antibody (N-term) Blocking Peptide
- References**

Huang,D., et.al., J. Cancer Res. Clin. Oncol. 136 (3), 395-401 (2010);Yang,Z.Q., et.al., Int. J. Cancer 125 (7), 1613-1621 (2009).

Synonyms FRP, FRP1, SARP2**Function**

Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP1 decreases intracellular beta-catenin levels (By similarity). Has antiproliferative effects on vascular cells, in vitro and in vivo, and can induce, in vivo, an angiogenic response. In vascular cell cycle, delays the G1 phase and entry into the S phase (By similarity). In kidney development, inhibits tubule formation and bud growth in metanephroi (By similarity). Inhibits WNT1/WNT4-mediated TCF- dependent transcription.

Cellular Location

Secreted. Note=Cell membrane or extracellular matrix-associated. Released by heparin-binding

Tissue Location

Widely expressed. Absent from lung, liver and peripheral blood leukocytes. Highest levels in heart and fetal kidney Also expressed in testis, ovary, fetal brain and lung, leiomyoma cells, myometrial cells and vascular smooth muscle cells. Expressed in foreskin fibroblasts and in keratinocytes

**SFRP1 Antibody (N-term) Blocking Peptide
- Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)